What were the outcomes of targeting a higher intra‑operative MAP (≥80 mmHg) versus the standard MAP target (≥65 mmHg) in adult ASA I‑III patients undergoing elective surgery?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Higher Intraoperative MAP Target (≥80 mmHg) Shows Benefit in High-Risk Hypertensive Patients

In high-risk hypertensive patients undergoing major abdominal surgery, targeting an intraoperative MAP ≥80 mmHg reduces major organ dysfunction and acute kidney injury compared to the standard MAP ≥65 mmHg target, though this benefit does not extend to unselected surgical populations.

Evidence in High-Risk Hypertensive Patients

The most recent and highest quality evidence comes from the HISTAP trial 1, a 2026 multicenter randomized trial of 630 hypertensive patients aged ≥60 years undergoing elective major abdominal surgery. This study demonstrated:

  • Primary composite outcome (mortality + major organ dysfunction) occurred in 38.1% with MAP ≥80 mmHg versus 48.9% with MAP ≥65 mmHg (RR 0.78,95% CI 0.65-0.93, P=0.006)
  • Acute kidney injury was significantly reduced: 23.5% versus 33.7% (P=0.005)
  • Mean achieved MAP was 88±9 mmHg in the treatment group versus 77±7 mmHg in controls

This finding is corroborated by an earlier 2017 Chinese trial 2 in 648 elderly hypertensive patients undergoing gastrointestinal surgery, which found that MAP control at 80-95 mmHg resulted in the lowest AKI incidence (6.3%) compared to both lower (65-79 mmHg: 13.5%) and higher (96-110 mmHg: 12.9%) targets.

Evidence in Unselected Surgical Populations

However, three 2026 meta-analyses examining broader surgical populations found no benefit from higher MAP targets:

  • A meta-analysis of 15 trials with 15,603 patients 3 showed no reduction in AKI (RR 0.95), acute myocardial injury (RR 1.02), or mortality (RR 1.00) with higher targets
  • Another meta-analysis of 9 RCTs with 14,658 patients 4 found no difference in 30-day mortality (RR 1.06), AKI, or myocardial injury
  • A third meta-analysis of individualized versus conventional management 5 in 4,017 patients showed no reduction in AKI (RR 0.88) or mortality (RR 0.96)

Delirium Reduction Signal

Both meta-analyses examining delirium found a potential benefit:

  • Higher targets reduced postoperative delirium (RR 0.73,95% CI 0.54-0.98) 3, though trial sequential analysis indicated insufficient evidence for firm conclusions
  • Individualized management also reduced delirium rates (RR 0.55,95% CI 0.35-0.88) 5

Clinical Algorithm

For high-risk hypertensive patients (age ≥60, chronic hypertension on home therapy, undergoing major abdominal surgery with additional risk factors):

  • Target intraoperative MAP ≥80 mmHg
  • Use protocolized fluid therapy and continuous hemodynamic monitoring
  • This reduces organ dysfunction primarily through prevention of mild-to-moderate AKI

For unselected surgical populations:

  • Standard MAP ≥65 mmHg remains appropriate
  • Higher targets do not improve major outcomes and may increase vasoactive drug requirements without clear benefit

Critical Caveats

The divergence between HISTAP's positive findings 1 and negative meta-analyses 3, 4, 5 likely reflects patient selection. HISTAP specifically enrolled high-risk hypertensive patients with protocolized care, while meta-analyses included heterogeneous populations where the intervention may have been diluted. The 2017 Chinese trial 2 supports that the "sweet spot" for elderly hypertensive patients is 80-95 mmHg—higher targets (96-110 mmHg) offered no additional benefit and required more vasoactive agents.

The key is identifying the right patient population: chronic hypertensive patients at high postoperative risk undergoing major abdominal surgery, not routine surgical cases.

Related Questions

What is a safe intra‑operative blood pressure for performing an open bilateral aponeurotic plate repair, inguinal floor repair, adductor fasciotomy with partial tendinolysis, nerve blocks, and complex closure?
How should acute postoperative hemorrhage‑induced hypotension be managed in an elderly patient with chronic kidney disease?
What pre‑operative blood pressure target is recommended for a hypertensive adult undergoing elective non‑cardiac surgery?
In adult ASA I‑III patients undergoing elective surgery, what intra‑operative hemodynamic parameter was used as the primary objective?
In a patient monitored with FloTrac who has a cardiac index of 1.8 L/min/m², stroke volume variation of 28 %, cardiac output of 2.9 L/min, mean arterial pressure of 70 mmHg, and heart rate of 105 bpm, should a vasoactive drug be added?
What were the results of the primary objective (postoperative recovery quality measured by the QoR‑15 questionnaire on postoperative day 1 and day 2) in the second study?
What vancomycin dose should be administered after each thrice‑weekly hemodialysis session for a 100‑kg patient with MRSA bacteremia?
In adult ASA I‑III patients undergoing elective surgery, what intra‑operative hemodynamic parameter was used as the primary objective?
What is Henoch‑Schönlein purpura (HSP)?
What is the recommended method for switching antidepressants to minimize the risk of a switch reaction?
What is the recommended anesthetic management for major abdominal surgery, including robotic and laparoscopic procedures?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.